EPO and cancer: Our data introduce Cibinetide as an appealing candidate for the treatment of bone loss either as a stand-alone therapy for osteolytic pathologies ranging from cancer to rheumatoid arthritis and osteoporosis, or in combination with EPO for patients with anemia or cancer.